Henry Meds Ideal Patient Profile: Who It's Best For (and Who Should Look Elsewhere)

What Henry Meds Actually Is

Henry Meds operates as a subscription-based telehealth platform focused on compounded hormone therapies and GLP-1 receptor agonists. The service connects patients with licensed prescribers through an asynchronous online intake, then ships compounded medications directly from partner pharmacies. It does not accept insurance for its GLP-1 program.

The company is real, its prescribers hold valid state licenses, and the pharmacies it works with are required to be licensed 503A compounding pharmacies or 503B outsourcing facilities. "legit" and "optimal for your situation" are separate questions. Patients should weigh the regulatory status of compounded drugs before starting.

What "Compounded" Means in Practice

Compounded GLP-1s are not the same product as brand-name Ozempic or Wegovy. The FDA has not evaluated them for safety, efficacy, or manufacturing consistency the way it reviews finished drug products. The FDA has historically permitted compounding of semaglutide and tirzepatide during documented shortage periods, but that status can change. As of early 2025, the FDA removed both semaglutide and tirzepatide from the shortage list, which has created legal uncertainty for compounders. Patients starting a compounded GLP-1 program should confirm their pharmacy's current compliance status before ordering.

How the Intake Process Works

New patients complete an online health questionnaire covering weight history, current medications, and relevant diagnoses. A prescriber reviews the intake, often within 24 to 48 hours, and issues a prescription if the patient qualifies. There is no synchronous video visit in the standard flow, though some states require a live encounter. Medications arrive by mail in multi-dose vials requiring self-injection.

Who Qualifies: The Clinical Criteria

The FDA-approved labeling for semaglutide 2.4 mg (Wegovy) defines the indicated population as adults with an initial BMI of 30 kg/m2 or higher, or 27 kg/m2 or higher in the presence of at least one weight-related comorbidity. Henry Meds uses essentially the same threshold because prescribers are ethically and legally bound to prescribe within evidence-based indications. [1]

Qualifying comorbidities at a BMI of 27 to 29.9 include type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, and cardiovascular disease. A patient with a BMI of 26 who simply wants to lose 15 pounds does not meet criteria and a responsible telehealth prescriber should decline.

Body Weight and BMI Requirements

The STEP-1 trial enrolled adults with a mean BMI of 37.9 kg/m2 and no diabetes. STEP-2 (N=1,210) enrolled adults with type 2 diabetes and a mean BMI of 35.7 kg/m2. The magnitude of weight loss correlated with baseline BMI and adherence to a caloric deficit, not with the delivery platform. [2]

Patients near the lower BMI cutoff (27 to 30) tend to lose a smaller absolute percentage of body weight. A meta-analysis of GLP-1 receptor agonists published in JAMA Internal Medicine (2023) found that patients with BMI <35 experienced roughly 8 to 10% total body weight loss vs. 12 to 16% in those with BMI above 35. [3]

Comorbidity Checklist

A patient meeting BMI criteria PLUS any of the following is a stronger clinical candidate for GLP-1 therapy regardless of delivery platform:

• Hemoglobin A1c between 5.7% and 6.4% (prediabetes)
• Fasting glucose above 100 mg/dL on two separate occasions
• Blood pressure consistently above 130/80 mmHg despite lifestyle changes
• Triglycerides above 150 mg/dL
• AHI above 5 on sleep study (obstructive sleep apnea)
• Prior cardiovascular event or established atherosclerotic disease

The 2023 American Heart Association obesity guideline explicitly states that "GLP-1 receptor agonist therapy is recommended as an adjunct to lifestyle intervention for adults with overweight or obesity and established cardiovascular disease or high cardiovascular risk." [4]

Who Should Not Use Henry Meds

Some patients need more clinical infrastructure than an async telehealth service provides. Exclusion criteria are not arbitrary; they reflect real pharmacological risks identified in clinical trials and FDA labeling.

Absolute Contraindications to GLP-1 Therapy

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia type 2 (MEN2)
• Known hypersensitivity to semaglutide or tirzepatide

These apply to brand-name and compounded versions equally. The boxed warning in the FDA labeling for Wegovy and Ozempic is unambiguous on thyroid C-cell tumor risk in rodent models, and the clinical implication is that any personal or family history of MTC is a hard stop. [5]

Situations Requiring More Intensive Monitoring

Patients with any of the following should discuss GLP-1 therapy with an endocrinologist or their primary care physician before using an async telehealth service:

• Active or recent pancreatitis
• Severe gastroparesis
• Stage 3 or worse chronic kidney disease (eGFR <45 mL/min/1.73m2)
• Gallbladder disease requiring ongoing management
• Type 1 diabetes or insulin-dependent type 2 diabetes with frequent hypoglycemia
• Active psychiatric illness or a history of eating disorders

Henry Meds intake forms flag some of these, but async review has limits. A patient with a complex medication list, recent hospitalization, or active organ disease deserves a face-to-face evaluation.

The Cost Structure: Is It Worth It?

Henry Meds positions itself as a low-cost alternative to brand-name GLP-1 prescriptions. Retail pricing for Wegovy runs approximately $1,349 per month without insurance, and insurance prior authorization rates remain unpredictable. Henry Meds compounded semaglutide is priced well below that mark, typically in the $200 to $300 per month range depending on dose.

The table below compares estimated monthly costs across the main options a cash-pay patient in the US faces:

| Option | Approx. Monthly Cost | FDA-Approved Product | Insurance Eligible | |---|---|---|---| | Wegovy (semaglutide 2.4 mg, brand) | $1,100 to $1,350 | Yes | Sometimes | | Ozempic (semaglutide 1 mg, brand, off-label for weight) | $900 to $1,000 | Yes (diabetes indication) | Rarely for weight | | Henry Meds compounded semaglutide | $200 to $297 | No | No | | Other telehealth compounders (e.g., Ro, Hims) | $199 to $399 | No | No | | Manufacturer savings card (Novo Nordisk) | $0 to $25/month (eligible commercially insured only) | Yes | Required |

For a patient who has confirmed insurance will not cover Wegovy and who meets the clinical criteria above, the cost argument for compounded semaglutide is straightforward. The risk trade-off is accepting a product not subject to FDA batch testing, without the pharmacovigilance infrastructure that post-market surveillance of brand-name drugs provides.

What the Subscription Includes

Henry Meds charges a monthly membership fee that covers the prescriber visit, ongoing messaging access to the clinical team, and medication. Dose titration happens through the app based on tolerability reporting. There are no separate lab fees baked into the model, which means patients are responsible for ordering their own metabolic panels if a prescriber requests baseline labs.

Henry Meds vs. Alternatives: A Direct Comparison

The compounded GLP-1 telehealth space now includes dozens of operators. Clinically meaningful differences between them are narrower than their marketing suggests, but a few structural factors matter.

Platform Structure

Ro Body and Hims/Hers Weight use similar async models at comparable price points. Some platforms offer optional video consultations. Calibrate pairs prescriptions with a dietitian coaching layer, at a higher monthly cost. Found offers both branded and compounded options with more frequent touchpoints. Henry Meds is among the leaner models, focused on cost reduction above added services.

Pharmacy Quality Variability

This is the most clinically significant variable across all compounded GLP-1 platforms. The FDA does not approve compounded drugs, but 503B outsourcing facilities are inspected by the FDA and must comply with Current Good Manufacturing Practice standards. 503A pharmacies are inspected by state boards. Potency variability in compounded semaglutide preparations has been reported in the literature. A 2023 analysis published by the FDA noted that some tested samples of compounded semaglutide contained incorrect active drug concentrations. [6]

Patients choosing any compounded GLP-1 service, including Henry Meds, should ask directly: Is the compounding pharmacy a 503A or 503B facility? Has it been inspected recently without a Form 483 for sterility or potency violations?

Clinical Oversight Depth

Henry Meds does not employ the same depth of dietitian or health coaching integration that higher-cost platforms do. For patients who have already established behavioral strategies and primarily need medication access, that is not a meaningful gap. For patients who have never structured a caloric deficit and need behavioral scaffolding alongside the medication, a platform with coaching is likely to produce better outcomes. The SCALE Obesity and Prediabetes trial (N=3,731) demonstrated that semaglutide 3 mg produced the greatest weight loss when paired with intensive behavioral intervention (diet and exercise counseling), not when used in isolation. [7]

What the Evidence Says About Compounded vs. Brand GLP-1s

No randomized controlled trial has directly compared compounded semaglutide to brand Wegovy in head-to-head fashion. The efficacy data that makes GLP-1s compelling comes entirely from trials using the branded, FDA-approved formulations.

The STEP program (STEP-1 through STEP-8) consistently showed that semaglutide 2.4 mg subcutaneous weekly produced 10 to 17% mean body weight reduction over 68 weeks depending on the population. [1][2] SURMOUNT-1 (N=2,539) showed tirzepatide 15 mg produced a mean 20.9% reduction in body weight at 72 weeks. [8]

Whether compounded semaglutide achieves identical pharmacokinetic behavior is unknown. The same active molecule may behave differently based on excipients, pH of the injection solution, and storage conditions. This is not a theoretical concern. The FDA issued a safety communication in 2023 noting reports of adverse events, including hospitalizations, associated with compounded semaglutide, some related to dosing errors from concentration mismatches between products. [6]

A reasonable interpretation: patients choosing compounded GLP-1s accept meaningful but not fully quantified uncertainty about product equivalence. That trade-off is worth characterizing honestly before starting.

Real-World Henry Meds Reviews: What Patients Report

Patient reviews of Henry Meds on third-party platforms (Trustpilot, Reddit forums like r/Semaglutide) follow a reasonably consistent pattern. Positive reviews emphasize the low cost, fast intake process, and accessibility for patients without GLP-1 insurance coverage. Negative reviews cluster around three themes: delayed shipments when pharmacy inventory was disrupted, slow responses to clinical questions through the app, and occasional issues with injection pen or vial quality.

These patterns are not unique to Henry Meds. They reflect structural limitations of the async compounded-medication telehealth model broadly. Any service operating at this price point is making trade-offs on staffing and response time.

The American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines note that "obesity pharmacotherapy is most effective when provided within a comprehensive obesity management program including structured lifestyle intervention." [9] Henry Meds does not currently offer structured lifestyle programming, and patient reviews confirm this gap is real.

How to Know If Henry Meds Is the Right Choice for You

The clearest way to think through this decision is to work through a short set of clinical questions. A patient who can answer yes to most of the following is a reasonable candidate:

1. Is my BMI 30 or higher, or 27 or higher with a documented comorbidity?
2. Have I tried structured lifestyle changes (caloric deficit, increased activity) for at least three to six months without reaching a medically meaningful response?
3. Does my prescriber or primary care physician know I am considering GLP-1 therapy?
4. Do I have no personal or family history of medullary thyroid carcinoma or MEN2?
5. Am I comfortable self-injecting a weekly subcutaneous medication from a vial?
6. Am I willing to confirm the dispensing pharmacy's 503A or 503B status and recent inspection history?
7. Do I understand that the product I receive is not FDA-approved and that dose accuracy cannot be guaranteed by the same mechanism as brand drugs?

If a patient answers yes to all seven, Henry Meds is a plausible low-cost access point. If the answer to questions 4, 5, or 6 is no, a different pathway is warranted.

A Note on the Regulatory Field as of 2025

The FDA removed semaglutide from its drug shortage list in February 2025 and tirzepatide shortly after. Compounding of drugs that are not on the shortage list is restricted under the Federal Food, Drug, and Cosmetic Act. 503A pharmacies may still compound for individual patients with a valid prescription if a specific documented need exists, but large-scale compounding by 503B outsourcing facilities became legally precarious after shortage list removal.

Henry Meds, like all compounded GLP-1 telehealth services, is navigating this shift. Patients who begin a compounded program should ask their provider what happens to their supply if the pharmacy stops compounding semaglutide or tirzepatide. Having a contingency plan, including whether a brand-name prescription with manufacturer savings support is feasible, is good clinical practice.

The FDA's formal guidance on compounded drug shortage policies is available directly through the agency. [10]